An ADC may show better response rates than chemotherapy, but its true benefit is compromised if toxicities lead to treatment discontinuation. As seen with failed PARP/IO combinations, if patients cannot tolerate a drug long enough, the regimen's overall effectiveness can become inferior to standard therapy.

Contrary to the standard 150mg starting dose, many clinicians begin abemaciclib at 100mg BID. Data from the TRADE trial and retrospective MonarchE analyses show this improves tolerability, reduces early dropouts, and maintains efficacy, as patients who dose-reduced to 100mg performed just as well.

The Phase 2 TRAIT study suggests starting adjuvant abemaciclib at a lower dose and escalating over several weeks significantly reduces early discontinuations due to side effects like diarrhea. This strategy helps more patients get through the initial high-toxicity period and remain on the effective dose for the full two-year course.

An Emory University study using a medication-tracking app found that anxiety and depression were significantly associated with lower adherence to oral CDK4/6 inhibitors. This provides data-driven evidence for the critical need to proactively screen for and manage mental health to ensure treatment efficacy.

Patients are often exhausted after primary treatment and surprised by the recommendation for two additional years of intensive oral therapy. Clinicians should introduce this possibility early in the treatment journey to manage expectations and prevent the patient from feeling overwhelmed later on.

The LIDERA trial showed that while jiridestrant and standard therapies had similar adverse event profiles, patients on jiridestrant had significantly lower discontinuation rates. This highlights that a patient's subjective experience of tolerability is a more critical factor for long-term adherence than a simple list of side effects.

When choosing an adjuvant CDK4/6 inhibitor for high-risk HR+ breast cancer, clinicians favor abemaciclib. The key deciding factors are its proven overall survival (OS) benefit from the MonarchE trial and a more appealing two-year treatment course, compared to ribociclib's three-year duration and not-yet-mature OS data.

When choosing between adjuvant CDK4/6 inhibitors for high-risk patients eligible for both, oncologists favor abemaciclib (monarchE). This preference is driven not just by overall survival data, but by the longer follow-up period *after* patients have completed therapy, ensuring the benefit is durable and the survival curves don't converge.

Data from the MONARCH-E and NATALY trials show that the benefit of adjuvant CDK4/6 inhibitors like abemaciclib and ribociclib persists and even increases after patients complete their 2-3 year treatment course. This sustained "carryover effect" suggests a lasting impact on disease biology rather than just temporary suppression.